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Summary
 
Interleukin (IL)-12 is a proinflammatory cytokine that contributes to innate resistance and to
the development of antigen-specific T cell responses. Among other effects, prostaglandin E2
(PGE2) inhibits the production of IL-12 by macrophages activated with lipopolysaccharide
(LPS). Here we investigated the effects of PGE2 on human dendritic cells (DCs) which de-
velop in the presence of GM-CSF and IL-4. We demonstrate that in the absence of LPS, PGE2
dose dependently stimulated the production of IL-12 by DCs. Although PGE2 alone stimu-
lated the production of low amounts of IL-12 only, it synergized with tumor necrosis factor
(TNF)-
 
a
 
 to induce high levels of IL-12 production by DCs. Addition of TNF-
 
a
 
 in the ab-
sence of PGE2 had no effect on IL-12 production. Conversely, in the presence of LPS, PGE2
inhibited IL-12 production by DCs in a dose-dependent manner. The combination of PGE2
and TNF-
 
a
 
 efficiently silenced mannose receptor–mediated endocytosis in DCs and readily in-
duced neo-expression of the CD83 antigen. In addition, the expression of various surface anti-
gens such as major histocompatibility complex class I and II, adhesion, as well as costimulatory
molecules was upregulated by this treatment. The effects of PGE2 on IL-12 synthesis and
CD83 expression could be mimicked by dibutyryl-cAMP and forskolin, indicating that they
were due to the intracellular elevation of cAMP levels. DC treated with PGE2 and TNF-
 
a
 
were most potent in stimulating allogeneic T cell proliferation. Our data demonstrate that
PGE2 contributes to the maturation of human DCs and that PGE2 can be a potent enhancer of
IL-12 production by human DCs.
 
T
 
issue injury induces an acute inflammatory response
mediated by components of innate resistance such as
macrophages which release proinflammatory factors (1). The
local inflammatory response at the site of injury is charac-
terized by the development of erythema, edema, and hyper-
algesia (2). In addition to several vasoactive factors such as
histamine, bradykinin, and nitric oxide (3, 4), prostaglan-
dins (PGs) contribute to this process. The therapeutic ben-
efit of nonsteroidal antiinflammatory drugs such as aspirin
or indomethacin in inflammatory diseases is based on the
inhibitory effects of these drugs on the synthesis of PGs (5).
The importance of PGs in the inflammatory process has
also been demonstrated in a rat model of carrageenan-
induced paw inflammation (2). In this model, the selective
neutralization of PGE2 by an antibody prevented the carra-
geenan-induced development of tissue edema and hyperal-
gesia. However, injection of PG into the skin causes mini-
mal swelling demonstrating that PGs on their own have
little inflammatory capacity. In contrast, in the presence of
other mediators, PGs can synergistically amplify the local
inflammatory response (6, 7). In contrast to these proin-
flammatory activities, PGs are also known to inhibit the
production of proinflammatory cytokines by macrophages
activated with LPS. PGE2 has been shown to inhibit the
LPS-induced human IL-12 production in whole blood cul-
tures (8) and the LPS-stimulated murine TNF-
 
a
 
 produc-
tion in cultured macrophages (9), supporting the view that
PGE2 acts as a suppressor of APC.
APCs link the inflammatory response to an Ag-specific
immunological response (1). Dendritic cells (DCs) are the
most potent APCs (10). DCs are highly responsive to in-
flammatory stimuli such as bacterial LPS and TNF-
 
a
 
 which
induce a series of phenotypic and functional changes in
DCs. These changes, which have been collectively referred
to as DC maturation (11), include the silencing of Ag up-
take by endocytosis (12), the upregulation of surface mole-
cules related to T cell activation (12), and the active pro-
duction of a number of cytokines including TNF-
 
a
 
 and
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IL-12 (13, 14). Upon local accumulation of TNF-
 
a
 
, DCs
migrate to the T cell areas of secondary lymphoid organs to
activate Ag-specific T cells (15).
In the present work, we have investigated the effects of
PGE2 on cultured human DCs. We show that PGE2 in the
absence of LPS stimulation is capable of inducing the pro-
duction of IL-12 by DCs. Although PGE2 on its own was
a weak stimulus of IL-12 production, PGE2 in concert
with TNF-
 
a
 
 induced the production of high levels of IL-12
in DC cultures. Moreover, the combination of PGE2 and
TNF-
 
a
 
 turned out to be a potent stimulus of DC maturation.
 
Materials and Methods
 
Media and Reagents.
 
The medium used in this study was
RPMI 1640 supplemented with 1% heat-inactivated (30 min,
56
 
8
 
C) pooled human AB serum, 50 U/ml penicillin, 50 
 
m
 
g/ml
streptomycin, 2 mM 
 
l
 
-glutamine, 10 mM Hepes, 0.1 mM nones-
sential amino acids, 1 mM pyruvate, and 5 
 
3
 
 10
 
2
 
5
 
 M 2-mercap-
toethanol (all from Boehringer Ingelheim Bioproducts, Vienna,
Austria). Human albumin (for intravenous use; Octapharma, Vi-
enna, Austria) was added to a final concentration of 2 mg/ml (
 
5
 
complete medium). Recombinant human GM-CSF (Leucomax;
1.11 
 
3
 
 10
 
7
 
 U/mg) was from Novartis (Basel, Switzerland). Re-
combinant human IL-4 (2 
 
3
 
 10
 
7
 
 U/mg) was supplied by the
Schering-Plough Research Institute (Kenilworth, NJ). Recombi-
nant human TNF-
 
a
 
 (10
 
7
 
 U/mg) was purchased from Genzyme
(Cambridge, MA). PGE2 was purchased from Sigma Chemical
Company (St. Louis, MO) and from Calbiochem-Novabiochem
International (San Diego, CA). Forskolin, 
 
N
 
-2-
 
O
 
-dibutyryl-cAMP
(db-cAMP), LPS (from 
 
Salmonella abortus equi
 
), and fluorescein-
ated Dextran (FITC-DX) were all from Sigma Chemical Co.
 
Culture of Human DCs.
 
DCs were generated from PBMCs as
described (16, 17). In brief, PBMCs were isolated from leuko-
cyte-enriched buffy coats by standard density gradient centrifuga-
tion on Ficoll-Paque (Pharmacia, Uppsala, Sweden), resuspended
in complete medium and 5.0 
 
3
 
 10
 
7
 
 PBMCs were allowed to ad-
here in 75-cm
 
2
 
 cell culture flasks (45 min 37
 
8
 
C). Nonadherent
cells were removed and adherent cells were cultured in 10 ml of
complete medium containing 1,000 U/ml of each GM-CSF and
IL-4. DCs were developed under essentially endotoxin-free con-
ditions as indicated by the absence of spontaneous TNF-
 
a
 
 pro-
duction (
 
,
 
5 pg/ml of TNF-
 
a
 
/5 
 
3
 
 10
 
5
 
 DC). On day 2, 5 ml of
fresh medium containing 1,000 U/ml of GM-CSF and IL-4 were
added. After 5 d of culture, cells were harvested, washed exten-
sively, and recultured in cytokine-containing medium at 3 
 
3
 
 10
 
5
 
cells/ml with or without inflammatory mediators. After 48 h, su-
pernatants were harvested for IL-12 ELISA assays and the cells
were analyzed for surface Ag expression by flow cytometry.
 
Flow Cytometric Measurement of Surface Ag Expression and En-
docytic Activity.
 
To determine surface Ag expression, cells (10
 
5
 
DC in 50 
 
m
 
l) were labeled with primary mAb in complete me-
dium followed by FITC-conjugated F(ab
 
9
 
)
 
2
 
 fragments of goat
anti–mouse Ig (Dako, Glostrup, Denmark). The following mAbs
were used: VIM-13 (IgM, anti-CD14, a gift of Dr. W. Knapp,
Vienna, Austria), G46-2.6 (IgG1, anti-HLA-ABC), L243 (IgG2a,
anti-HLA-DR), HB-15a (IgG2b, anti-CD83), 84H10 (IgG1, anti-
CD54), AIDC58 (IgG2a, anti-CD58), BB1 (IgM, anti-CD80),
BU63 (IgG1, anti-CD86), 5C3 (IgG1, anti-CD40), 1G10 (IgG1,
anti-CD43), G44-26 (IgG2b, anti-CD44). Washes were in HBSS
containing 0.2% albumin. After the last wash, the cells were stored
in HBSS containing 0.2% albumin and 2% formaldehyde.
The endocytic activity of DCs was measured as described pre-
viously (12). FITC-DX was used to measure mannose receptor–
mediated endocytosis. Cells (10
 
5
 
) were incubated with FITC-DX
(0.5 mg/ml) for 30 min at 37
 
8
 
C (control at 0
 
8
 
C) and then washed
extensively. The samples were analyzed on a FACScan
 
Ò
 
 (Becton
Dickinson, Mountain View, CA). Data were analyzed and pre-
sented using CellQuest
 
Ò
 
 software from Becton Dickinson.
 
Quantitation of IL-12.
 
Day-5 DCs (3 
 
3
 
 10
 
5
 
 cells/ml) were
incubated for 48 h with various stimuli and IL-12 was measured
in culture supernatants by ELISA using a commercially available
kit (Genzyme) that detects both IL-12 p40 and the bioactive IL-12
p70 heterodimer consisting of p40 and p35. IL-12 was quanti-
tated using a microtiter plate reader.
 
T Cell Proliferation Assay.
 
DCs were either untreated or treated
with TNF-
 
a
 
, PGE2, or PGE2 plus TNF-
 
a
 
 for 48 h. Irradiated
(3,000 rad) DCs (1 
 
3
 
 10
 
3
 
 or 5 
 
3
 
 10
 
4
 
) were then cultured with a
constant number of 2 
 
3
 
 10
 
5
 
 allogeneic T cells in 96-well flat-bot-
tomed tissue culture plates in medium containing 5% pooled hu-
man serum. T cell proliferation was measured as [
 
3
 
H]thymidine
incorporation (1 
 
m
 
Ci/well; 6.7 Ci/mmol, New England Nuclear,
Boston, MA). Cells were pulsed during the last 16 h of a 5-d cul-
ture period, harvested onto glass fiber filters using a Skatron cell
harvester (Skatron Instruments, Lier, Norway), and analyzed in a
liquid scintillation counter. Results are expressed as the mean
cpm of triplicate wells 
 
6
 
 SD.
 
Results
 
PGE2 Stimulates IL-12 Production in Human DCs.
 
Day-5
DCs were exposed to graded doses of PGE2, and IL-12
was determined in culture supernatants after 48 h. Fig. 1 
 
A
Figure 1. Stimulatory effects of PGE2 on IL-12 production by human
DCs. Day-5 DCs were incubated with graded doses of PGE2 either alone
(A) or in the presence of a constant dose of LPS (B) or TNF-a (C). Con-
versely, DCs were also incubated with graded doses of TNF-a in the
presence of a constant dose of PGE2 (D). After 48 h of culture, superna-
tants were harvested and IL-12 levels were determined using a specific
ELISA. Dose-dependent responses from two out of four independent ex-
periments are shown. 
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demonstrates that PGE2 stimulated IL-12 production in a
dose-dependent fashion. However, the total amount of
IL-12 induced by PGE2 was relatively low. PGE2-depen-
dent IL-12 production by DCs occurred in the absence of
endogenous TNF-
 
a
 
 production (data not shown). TNF-
 
a
 
has been described to enhance IL-12 production in the
context of LPS stimulation (18). Therefore, we tested the
effects of combinations of PGE2 and TNF-
 
a
 
 on IL-12 pro-
duction by DCs. In the presence of TNF-
 
a
 
, PGE2 dose
dependently stimulated high level IL-12 production in
DCs (Fig. 1 
 
C
 
). Conversely, the level of IL-12 production
also depended on the dose of TNF-
 
a
 
 (Fig. 1 
 
D
 
). The ef-
fects of PGE2 and TNF-
 
a
 
 were synergistic since TNF-
 
a
 
alone completely failed to induce IL-12 production by DCs
(Fig. 1 
 
C
 
). In contrast, PGE2 inhibited the LPS-induced
IL-12 production by DCs (Fig. 1 
 
B
 
) confirming previous
observations (8). PGE2 from two different commercial sources
were used with consistent results.
 
PGE2 and TNF-
 
a
 
 Cooperate to Activate Human DCs.
 
IL-12 production by DCs is always associated with DC ac-
tivation which can be induced by treatment with LPS (14),
BCG (13), a monocyte-conditioned medium (19, 20), or
by cross-linking of the CD40 Ag (21). DC activation,
which has also been referred to as DC maturation, is char-
acterized by the neo-expression of the CD83 Ag (22), by
the upregulation of molecules related to Ag presentation
(12, 22), and by the downmodulation of endocytic activity
(12, 23). Therefore, we then tested the effects of PGE2 and
TNF-
 
a
 
 on the process of DC maturation.
The combination of PGE2 and TNF-
 
a
 
 turned out to be
potent in inducing CD83 expression in DCs (Fig. 2 
 
A
 
). Ad-
dition of PGE2 (1 
 
m
 
M) along with TNF-
 
a
 
 (1,000 U/ml)
induced CD83 expression in 75% of the cells within 24 h
(data not shown) and in almost all cells within 48 h (Fig. 2 
 
A
 
).
Addition of either substance alone also induced CD83 ex-
pression, although to a smaller extent (Fig. 2 
 
A
 
). Moreover,
treatment with PGE2 plus TNF-
 
a
 
 efficiently upregulated
the expression of MHC class I and II molecules, adhesion
molecules (CD54, CD58), and costimulatory molecules
(CD80, CD86) in DCs (Fig. 3). The expression of CD40
and CD44 was also enhanced. Inspection of these cells by
phase contrast microscopy revealed a pronounced dendritic
morphology with numerous large veils, a feature of mature
DCs (data not shown; reference 10). Conversely, the ability
to capture soluble Ag (DX) by mannose receptor–mediated
endocytosis was almost completely downregulated in DCs
cultured in the presence of PGE2 and TNF-
 
a
 
 (Fig. 2 
 
B
 
).
Again, either substance alone also downmodulated Ag up-
take, although less efficiently.
Figure 2. Regulatory effects of PGE2 on CD83 expression and Ag up-
take. (A) Day-5 DCs were incubated with PGE2 (1 mM), TNF-a (1,000
U/ml), LPS (10 ng/ml), or PGE2 plus TNF-a. After 48 h, cells were har-
vested and CD83 expression was measured by flow cytometry. The iso-
type control (IgG2b) is also presented (dotted lines). (B) Day-5 DCs were
incubated with PGE2 (1 mM), TNF-a (1,000 U/ml), or PGE2 plus
TNF-a. After 24 h, cells were harvested and incubated with FITC-DX
for 30 min at 378C (controls at 08C, dotted lines), washed, and analyzed by
flow cytometry.
Figure 3. Phenotypic changes of DCs cultured with PGE2 and TNF-a.
Day-5 DCs were recultured in the absence (dotted lines) or presence of
PGE2 (1 mM) plus TNF-a (1,000 U/ml) (bold lines) for 48 h and analyzed
by flow cytometry for the surface expression of the indicated Ag using the
antibodies listed in Materials and Methods.1606 PGE2 Stimulates IL-12 Production in Human Dendritic Cells
PGE2 Effects on DCs Are Mimicked by Nonphysiologic
Modulators of cAMP. Most of the effects of PGE2 are me-
diated by the intracellular second messenger cAMP (24).
Therefore, PGE2 effects can be mimicked by nonphysio-
logic modulators of cAMP such as forskolin and db-cAMP.
To investigate the mechanism of the stimulatory effects of
PGE2 on DCs, we tested the effects of forskolin or db-
cAMP either alone or in the presence of TNF-a on IL-12
synthesis and CD83 expression in human DCs. Fig. 4 A
demonstrates that db-cAMP (100 mM) stimulated low level
IL-12 production and synergized with TNF-a to induce
substantial IL-12 production by DCs. CD83 expression was
also induced by db-cAMP (Fig. 4 B). Forskolin at 10 mM
failed to induce IL-12 production (Fig. 4 A). Higher con-
centrations of forskolin could not be tested due to the high
toxicity of this compound. However, in the presence of
TNF-a forskolin at 10 mM induced measurable IL-12 pro-
duction (Fig. 4 A). Forskolin also induced CD83 expres-
sion (Fig. 4 B).
PGE2 Enhances the Accessory Cell Capacity of Human
DCs. High levels of adhesion molecules expressed by
mature DCs (Fig. 3) contribute to the T cell stimulatory
potential of DCs by facilitating the formation of clusters with
T cells (11). DCs treated with PGE2 and TNF-a were most
potent in cluster formation with allogeneic T cells (data not
shown). Either substance alone also enhanced cluster for-
mation, although at a lower level.
The formation of clusters serves to establish close con-
tacts between DCs and T cells, thereby favoring TCR en-
gagement and T cell activation (11). Fig. 5 shows that DCs
treated with PGE2 and TNF-a also exhibited the highest
capacity to stimulate allogeneic T cell proliferation. Treat-
ment of DCs with either substance alone also enhanced T cell
proliferation, but to a smaller extent (Fig. 5).
Discussion
PGE2 has been demonstrated to be a potent inhibitor of
the LPS-induced human IL-12 production (8). In the
present work, we demonstrate that PGE2 in the absence of
LPS is capable of stimulating IL-12 production by human
DCs. PGE2 per se was a weak stimulus (Fig. 1 A), but was
synergized with TNF-a to induce the production of high
levels of IL-12 by DC (Fig. 1, C and D). This is consistent
with previous reports that demonstrated that PGs are rela-
tively weak inflammatory stimuli, but potentiate inflamma-
tory reactions in the presence of other mediators (6, 7).
Moreover, we show that PGE2 contributes to DC matura-
tion (11) which is characterized by the downmodulation of
mannose receptor–mediated endocytosis (Fig. 2 B), by the
upregulation of molecules that are important for T cell ac-
tivation (Fig. 3), as well as by the neo-expression of the
CD83 Ag (Fig. 2 A). DC maturation can also be induced
by monocyte-conditioned medium (19, 20). Our findings
suggest that PGE2, which is released by activated mono-
cytes, contributes to the DC maturation function of mono-
cyte-conditioned medium. PGE2-treated DCs also exhib-
ited an increased accessory cell potential which was evident
as an enhanced capacity to form clusters with allogeneic T
cells (data not shown) and to stimulate allogeneic T cell
proliferation (Fig. 5).
Our data suggest the involvement of a cAMP signaling
pathway in DC maturation since addition of db-cAMP and
forskolin, which are known to increase intracellular levels
of cAMP (24), mimicked the effects of PGE2. Similarly, in
human monocytes, cAMP synergized with TNF-a to up-
regulate the synthesis of IL-1b (25), suggesting that the
TNF-a signal transduction pathway that leads to intracellu-
lar accumulation of ceramide (26) and the PG pathway via
elevation of the intracellular second messenger cAMP (24),
cooperate to induce cytokine production by APCs (refer-
ence 25 and this work).
DCs obviously produce IL-12 at different anatomical
sites and different states of their development. DCs residing
in peripheral tissues are immature. Tissue DCs are actively
endocytosing Ag. DCs cultured with GM-CSF and IL-4
exhibit high endocytic capacity and appear to correspond
to these tissue DCs (11). At this state, PGE2 has stimulatory
effects and strongly enhances IL-12 synthesis in the presence
of TNF-a (Fig. 1, C and D). The capability of immature
DCs to produce large amounts of IL-12 in response to in-
flammatory conditions reflects the contribution of DCs to
Figure 4. Mimicry of PGE2 effects on IL-12 synthesis and CD83 ex-
pression by nonphysiologic modulators of cAMP. Day-5 DCs were incu-
bated with db-cAMP (100 mM) or forskolin (10 mM) either alone or in
combination with TNF-a (1,000 U/ml). After 48 h, supernatants were
analyzed for the presence of IL-12 using a specific ELISA (A) and the cells
were analyzed for CD83 expression by flow cytometry (B). Data are
given as mean 6 SEM of four independent experiments.
Figure 5. T cell stimulatory ca-
pacity of DCs cultured with
PGE2. Day-5 DCs were recul-
tured in the absence or presence
of PGE2 (10 mM), TNF-a
(1,000 U/ml), or PGE2 plus
TNF-a. After 48 h the cells were
washed, irradiated, and DCs were
used as stimulators of allogeneic
T cell proliferation. Proliferation
was monitored by measuring
[methyl-3H]thymidine uptake on
day 5 of coculture. Each value
represents the mean cpm of trip-
licate cultures with SD.1607 Rieser et al. Brief Definitive Report
innate resistance and primarily functions to activate NK cells
(27). Accumulation of inflammatory mediators then prompts
DCs to migrate to the T cell areas of secondary lymphoid
organs where they present Ags to recirculating T cells. Dur-
ing contact with Ag-specific T cells, IL-12 produced by
DCs after triggering of their CD40 antigen by T cell CD40
ligand (28, 29) favors the generation of Th1 type T cell re-
sponses. At this level, PGE2 appears to inhibit T cell activa-
tion and to selectively suppress the production of Th1 cy-
tokines (30–32). Taken together, PGE2 appears to exert
both stimulatory and inhibitory effects on the development
of Th1 type T cell responses depending on the site of
PGE2 action.
The combination of PGE2 and TNF-a induced full DC
activation (Figs. 2 and 3), which included IL-12 produc-
tion by DCs (Fig. 1). This mechanism of activation, which
is independent of infectious Ags, may play a role in autoim-
mune diseases. Mononuclear cells derived from inflamed
rheumatoid arthritis joints exhibited enhanced production
of both PG (33) and TNF-a (34), which can cooperate to
increase IL-12 production (Fig. 1). IL-12 production is in-
deed increased in synovial mononuclear cells from arthritis
patients (35) and in tubular epithelial cells of mice with lu-
pus nephritis (36). Moreover, IL-12 is known to accelerate
the development of autoimmune diseases (37). Furthermore,
the induction of DC maturation by PGE2 and TNF-a in
the inflammatory lesions may result in continuous presen-
tation of self Ag by fully activated DCs in vivo, and may
thereby support the development of autoimmunity.
In conclusion, our data indicate that PGE2 must also be
considered an important activator of human DCs. The
beneficial effect of nonsteroidal antiinflammatory drugs in
inflammatory diseases such as rheumatoid arthritis may re-
late to the inhibition of PGE2-mediated DC activation.
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